Literature DB >> 16080954

Loss of DNA copy number of 10q is associated with aggressive behavior of leiomyosarcomas: a comparative genomic hybridization study.

Jie Hu1, Uma N M Rao, Suhagi Jasani, Vineesh Khanna, Kenneth Yaw, Urvashi Surti.   

Abstract

Leiomyosarcomas (LMS) account for 10-20% of all soft tissue sarcomas. We analyzed 10 primary, 5 metastatic, and 2 recurrent extrauterine LMS. Genomic imbalances were detected in 15 out of the 17 tumors. The most common regions of loss were 13q (59%, 10 of 17), 10q (59%, 10 of 17), 2q (35%, 6 of 17), and 16q (29%, 5 of 17). The most common region of gain was 5p (35%, 6 of 17). High-level gain of DNA copy number was detected in 6p and 17p. Loss of function of tumor suppressor genes or the activation of oncogenes (or both of these factors) resulting from these copy number changes might play an important role in the development of extrauterine LMS. Large tumors and tumors with metastasis showed 10q deletions. Gain of 5p was detected only in G3 tumors. These findings are consistent with our earlier study on uterine LMS and indicate that loss of 10q and gain of 5p are associated with an aggressive behavior of LMS. A larger series of cases is needed to confirm these results.

Entities:  

Mesh:

Year:  2005        PMID: 16080954     DOI: 10.1016/j.cancergencyto.2005.01.011

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  19 in total

Review 1.  Chromosome 6p amplification and cancer progression.

Authors:  Gda C Santos; M Zielenska; M Prasad; J A Squire
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

Review 2.  Soft tissue sarcomas with complex genomic profiles.

Authors:  Louis Guillou; Alain Aurias
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

3.  Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors.

Authors:  Antti Ylipää; Kelly K Hunt; Jilong Yang; Alexander J F Lazar; Keila E Torres; Dina C Lev; Matti Nykter; Raphael E Pollock; Jonathan Trent; Wei Zhang
Journal:  Cancer       Date:  2010-09-03       Impact factor: 6.860

Review 4.  Genomic characteristics of soft tissue sarcomas.

Authors:  Fredrik Mertens; Ioannis Panagopoulos; Nils Mandahl
Journal:  Virchows Arch       Date:  2009-02-03       Impact factor: 4.064

5.  Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors.

Authors:  Bernadette Liegl-Atzwanger; Ellen Heitzer; Karin Flicker; Stephanie Müller; Peter Ulz; Ozlen Saglam; Fattaneh Tavassoli; Mojgan Devouassoux-Shisheboran; Jochen Geigl; Farid Moinfar
Journal:  Mod Pathol       Date:  2016-07-01       Impact factor: 7.842

6.  Curcumin targets the AKT-mTOR pathway for uterine leiomyosarcoma tumor growth suppression.

Authors:  Tze Fang Wong; Takashi Takeda; Bin Li; Kenji Tsuiji; Akiko Kondo; Mari Tadakawa; Satoru Nagase; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2013-05-11       Impact factor: 3.402

Review 7.  Genetic aberrations in soft tissue leiomyosarcoma.

Authors:  Jilong Yang; Xiaoling Du; Kexin Chen; Antti Ylipää; Alexander J F Lazar; Jonathan Trent; Dina Lev; Raphael Pollock; Xishan Hao; Kelly Hunt; Wei Zhang
Journal:  Cancer Lett       Date:  2008-07-22       Impact factor: 8.679

8.  Targeted exome sequencing profiles genetic alterations in leiomyosarcoma.

Authors:  Narasimhan P Agaram; Lei Zhang; Francois LeLoarer; Tarik Silk; Yun-Shao Sung; Sasinya N Scott; Deborah Kuk; Li-Xuan Qin; Michael F Berger; Cristina R Antonescu; Samuel Singer
Journal:  Genes Chromosomes Cancer       Date:  2015-11-06       Impact factor: 5.006

9.  Genomic signatures predict poor outcome in undifferentiated pleomorphic sarcomas and leiomyosarcomas.

Authors:  Sara Martoreli Silveira; Rolando Andre Rios Villacis; Fabio Albuquerque Marchi; Mateus de Camargo Barros Filho; Sandra Aparecida Drigo; Cristovam Scapulatempo Neto; Ademar Lopes; Isabela Werneck da Cunha; Silvia Regina Rogatto
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

10.  Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus.

Authors:  Vicki L Keedy
Journal:  Onco Targets Ther       Date:  2012-08-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.